1
|
Utami N, Nurdiani D, Hariyatun H, Putro EW, Patria FP, Kusharyoto W. Full-length versus truncated α-factor secretory signal sequences for expression of recombinant human insulin precursor in yeast Pichia pastoris: a comparison. J Genet Eng Biotechnol 2023; 21:67. [PMID: 37212962 DOI: 10.1186/s43141-023-00521-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Accepted: 05/11/2023] [Indexed: 05/23/2023]
Abstract
BACKGROUND Human insulin was the first FDA-approved biopharmaceutical drug produced through recombinant DNA technology. The previous studies successfully expressed recombinant human insulin precursors (HIP) in Pichia pastoris truncated and full-length α-factor recombinant clones. The matting α-factor (Matα), a signal secretion, direct the HIP protein into the culture media. This study aimed to compare the HIP expression from full-length and truncated α-factor secretory signals clones that grown in two types of media, buffered methanol complex medium (BMMY) and methanol basal salt medium (BSMM). RESULTS ImageJ analysis of the HIP's SDS-PAGE shows that the average HIP expression level of the recombinant P. pastoris truncated α-factor clone (CL4) was significantly higher compared to the full-length (HF7) when expressed in both media. Western blot analysis showed that the expressed protein was the HIP. The α-factor protein structure was predicted using the AlphaFold and visualized using UCSF ChimeraX to confirm the secretion ability for both clones. CONCLUSIONS CL4 clone, which utilized a truncated α-factor in the P. pastoris HIP expression cassette, significantly expressed HIP 8.97 times (in BMMY) and 1.17 times (in BSMM) higher than HF7 clone, which used a full-length α-factor secretory signal. This research confirmed that deletion of some regions of the secretory signal sequence significantly improved the efficiency of HIP protein expression in P. pastoris.
Collapse
Affiliation(s)
- Nuruliawaty Utami
- Research Center for Genetic Engineering, National Research and Innovation Agency (BRIN), Cibinong, Bogor, 16911, Indonesia.
| | - Dini Nurdiani
- Research Center for Genetic Engineering, National Research and Innovation Agency (BRIN), Cibinong, Bogor, 16911, Indonesia
| | - Hariyatun Hariyatun
- Research Center for Genetic Engineering, National Research and Innovation Agency (BRIN), Cibinong, Bogor, 16911, Indonesia
| | - Eko Wahyu Putro
- Research Center for Applied Microbiology, National Research and Innovation Agency (BRIN), Cibinong, Bogor, 16911, Indonesia
| | - Fadillah Putri Patria
- Laboratory Department, Indonesia International Institute for Life Sciences (i3L), Jakarta, Timur, 13210, Indonesia
| | - Wien Kusharyoto
- Research Center for Genetic Engineering, National Research and Innovation Agency (BRIN), Cibinong, Bogor, 16911, Indonesia
| |
Collapse
|
2
|
Caballero-Pérez A, Viader-Salvadó JM, Herrera-Estala AL, Fuentes-Garibay JA, Guerrero-Olazarán M. Buried Kex2 Sites in Glargine Precursor Aggregates Prevent Its Intracellular Processing in Pichia pastoris Mut s Strains and the Effect of Methanol-Feeding Strategy and Induction Temperature on Glargine Precursor Production Parameters. Appl Biochem Biotechnol 2021; 193:2806-2829. [PMID: 33931817 DOI: 10.1007/s12010-021-03567-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Accepted: 04/08/2021] [Indexed: 11/30/2022]
Abstract
Glargine is a long-acting insulin analog with less hypoglycemia risk. Like human insulin, glargine is a globular protein composed of two polypeptide chains linked by two disulfide bonds. Pichia pastoris KM71 Muts strains were engineered to produce and secrete insulin glargine through the cleavage of two Kex2 sites. Nevertheless, the recombinant product was the single-chain insulin glargine (glargine precursor) instead of the expected double-chain glargine. Molecular model analysis of the dimeric and hexameric forms of the single-chain glargine showed buried Kex2 sites that prevent intracellular glargine precursor processing. The effect of the methanol-feeding strategy (methanol limited fed-batch vs. methanol non-limited fed-batch) and the induction temperature (28 °C vs. 24 °C) on the cell growth and production parameters in bioreactor cultures was also evaluated. Exponential growth at a constant specific growth rate was observed in all the cultures. The volumetric productivities and specific substrate consumption rates were directly proportional to the specific growth rate. The lower temperature led to increased metabolic activity of the yeast cells, which increased the specific growth rate. The methanol non-limited fed-batch culture at 24 °C showed the highest values for the process parameters. After 75 h of induction, 0.122 g/L of glargine precursor was obtained from the culture medium.
Collapse
Affiliation(s)
- Abel Caballero-Pérez
- Instituto de Biotecnología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, UANL, 66455, San Nicolás de los Garza, N.L, Mexico
| | - José María Viader-Salvadó
- Instituto de Biotecnología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, UANL, 66455, San Nicolás de los Garza, N.L, Mexico
| | - Ana Lucía Herrera-Estala
- Instituto de Biotecnología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, UANL, 66455, San Nicolás de los Garza, N.L, Mexico
| | - José Antonio Fuentes-Garibay
- Instituto de Biotecnología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, UANL, 66455, San Nicolás de los Garza, N.L, Mexico
| | - Martha Guerrero-Olazarán
- Instituto de Biotecnología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, UANL, 66455, San Nicolás de los Garza, N.L, Mexico.
| |
Collapse
|
3
|
Thakur G, Hebbi V, Parida S, Rathore AS. Automation of Dead End Filtration: An Enabler for Continuous Processing of Biotherapeutics. Front Bioeng Biotechnol 2020; 8:758. [PMID: 32719791 PMCID: PMC7350908 DOI: 10.3389/fbioe.2020.00758] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2020] [Accepted: 06/15/2020] [Indexed: 12/17/2022] Open
Abstract
Dead end filtration is a critical unit operation that is used for primary and secondary clarification during manufacturing of both microbial and mammalian cell based biotherapeutics. Dead end filtration is conventionally done in batch mode and requires filter pre-sizing using extensive scouting studies, along with filter over-sizing before deployment to handle potential variability. However, continuous manufacturing processes require consistent use of dead-end filtration over weeks or months, with potential unpredictable variations in feed stream attributes, which is a challenge currently facing the industry. In this work, a dead-end filtration skid is designed for continuous depth filtration, incorporating multiple small-sized filters along with turbidity, and pressure sensors with immediate switching to a fresh filter whenever turbidity or pressure breakthrough above a pre-determined cut-off is detected in real time. The skid has been successfully tested for manufacturing of granulocyte colony stimulating factor from Escherichia coli, human serum albumin from Pichia pastoris, and a monoclonal antibody therapeutic from CHO cells. The proposed skid can be directly applied for any dead-end filtration application with minimal prior scouting studies or sizing calculations for scale-up. It is a useful solution for continuous processing trains where the nature of the feed, such as its turbidity or host cell proteins content, may change over long continuous campaigns, rendering previous sizing calculations inaccurate. The skid also allows significant cost savings by eliminating the sizing safety factor of 1.5-2x which is generally added before filter deployment at manufacturing scale.
Collapse
Affiliation(s)
| | | | | | - Anurag S. Rathore
- Department of Chemical Engineering, Indian Institute of Technology Delhi, New Delhi, India
| |
Collapse
|
4
|
Zhang Y, Liang Q, Zhang C, Zhang J, Du G, Kang Z. Improving production of Streptomyces griseus trypsin for enzymatic processing of insulin precursor. Microb Cell Fact 2020; 19:88. [PMID: 32284060 PMCID: PMC7155311 DOI: 10.1186/s12934-020-01338-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2020] [Accepted: 03/23/2020] [Indexed: 02/07/2023] Open
Abstract
Background Trypsin has many applications in food and pharmaceutical manufacturing. Although commercial trypsin is usually extracted from porcine pancreas, this source carries the risks of infectivity and immunogenicity. Microbial Streptomyces griseus trypsin (SGT) is a prime alternative because it possesses efficient hydrolysis activity without such risks. However, the remarkable hydrolysis efficiency of SGT causes autolysis, and five autolysis sites, R21, R32, K122, R153, and R201, were identified from its autolysate. Results The tbcf (K101A, R201V) mutant was screened by a directed selection approach for improved activity in flask culture (60.85 ± 3.42 U mL−1, increased 1.5-fold). From the molecular dynamics simulation, in the K101A/R201V mutant the distance between the catalytical residues D102 and H57 was shortened to 6.5 Å vs 7.0 Å in the wild type, which afforded the improved specific activity of 1527.96 ± 62.81 U mg−1. Furthermore, the production of trypsin was increased by 302.8% (689.47 ± 6.78 U mL−1) in a 3-L bioreactor, with co-overexpression of chaperones SSO2 and UBC1 in Pichia pastoris. Conclusions SGT protein could be a good source of trypsin for insulin production. As a result of the hydrolysates analysis and direct selection, the activity of the tbcf (K101A, R201V) mutant increased 1.5-fold. Furthermore, the production of trypsin was improved threefold by overexpressing chaperone protein in Pichia pastoris. Future studies should investigate the application of SGT to insulin and pharmaceutical manufacturing.
Collapse
Affiliation(s)
- Yunfeng Zhang
- Key Laboratory of Industrial Biotechnology, Ministry of Education, Jiangnan University, 1800 Lihu Road, Wuxi, 214122, Jiangsu, China.,The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, 214122, China.,Center for Synthetic Biochemistry, Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technologies, Shenzhen, China
| | - Qixing Liang
- Key Laboratory of Industrial Biotechnology, Ministry of Education, Jiangnan University, 1800 Lihu Road, Wuxi, 214122, Jiangsu, China
| | - Chuanzhi Zhang
- Bio-Pharmaceutical Research Institute Lian Yun Gang Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Lianyungang, Jiangsu, China
| | - Juan Zhang
- Key Laboratory of Industrial Biotechnology, Ministry of Education, Jiangnan University, 1800 Lihu Road, Wuxi, 214122, Jiangsu, China
| | - Guocheng Du
- Key Laboratory of Industrial Biotechnology, Ministry of Education, Jiangnan University, 1800 Lihu Road, Wuxi, 214122, Jiangsu, China.,The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, 214122, China
| | - Zhen Kang
- Key Laboratory of Industrial Biotechnology, Ministry of Education, Jiangnan University, 1800 Lihu Road, Wuxi, 214122, Jiangsu, China. .,The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, 214122, China.
| |
Collapse
|
5
|
Wu J, Gong G, Han S, Zhang W, Hu Y, Xie L. Expression, purification, and characterization of the Degludec precursor DesB30. Protein Expr Purif 2019; 161:28-39. [PMID: 31039402 DOI: 10.1016/j.pep.2019.04.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2019] [Revised: 02/28/2019] [Accepted: 04/23/2019] [Indexed: 10/26/2022]
Abstract
Diabetes is a chronic metabolic disease, for which recombinant human insulin is the most effective and mainstream treatment. DesB30 is an insulin analogue in which the B chain lacks amino acid 30 (Thr) compared with human insulin. This analogue can be used to produce the long-acting insulin Degludec or Detemir. In this study, a spacer peptide was added before the sequence of DesB30 and the C-peptide was replaced with AAK, a short connecting peptide. The target gene was cloned under the control of AOX1 and expressed as a secretory protein in Pichia pastoris. A high-yield recombination strain was selected by screening for resistance to G418. The basal salts medium was optimized and a lower salt concentration medium was found to show the best effects. Both media were used to compare the yield of high-density fermentation. The maximum yield reached 4.51 g/L in 1/2 basal salt medium, which is the highest reported yield to date. The insulin precursor, which is single-stranded, was purified by weak cation exchange chromatograph and preparative reversed-phase high-performance liquid chromatography (RP-HPLC), from which 73.39% of product was recovered at over 95% purity. The double-stranded protein (DesB30) was obtained by digesting the insulin precursor with trypsin. Using preparative RP-HPLC, the product was obtained with over 95% purity. Finally, the structure of DesB30 was confirmed.
Collapse
Affiliation(s)
- Junyi Wu
- Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, PR China
| | - Guihua Gong
- Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, PR China
| | - Shu Han
- Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, PR China
| | - Wei Zhang
- Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, PR China
| | - Youjia Hu
- Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, PR China
| | - Liping Xie
- Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, PR China.
| |
Collapse
|
6
|
Wang J, Wang X, Shi L, Zhang Y, Zhou X, Cai M. Reduced methanol input induces increased protein output by AOX1 promoter in a trans-acting elements engineered Pichia pastoris. ACTA ACUST UNITED AC 2018; 45:25-30. [DOI: 10.1007/s10295-017-1988-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Accepted: 11/06/2017] [Indexed: 10/18/2022]
Abstract
Abstract
High oxygen consumption and heat release caused by methanol catabolism usually bring difficulties to industrial scale-up and cost for protein expression driven by methanol-induced AOX1 promoter in Pichia pastoris. Here, reduced methanol feeding levels were investigated for expression of insulin precursor in a trans-acting elements engineered P. pastoris strain MF1-IP. Insulin precursor expression level reached 6.69 g/(L supernatant) at the methanol feeding rate of 6.67 mL/(h·L broth), which was 59% higher than that in the wild-type strain WT-IP at the methanol feeding rate of 12 mL/(h·L broth). Correspondingly, the insulin precursor expression level in fermentation broth and maximum specific insulin precursor production rate was 137 and 77% higher than the WT-IP, respectively. However, oxygen consumption and heat evolution were reduced, and the highest oxygen consumption rate and heat evolution rate of the MF1-IP were 18.0 and 37.7% lower than the WT-IP, respectively.
Collapse
Affiliation(s)
- Jinjia Wang
- 0000 0001 2163 4895 grid.28056.39 State Key Laboratory of Bioreactor Engineering East China University of Science and Technology 130 Meilong Road 200237 Shanghai China
| | - Xiaolong Wang
- 0000 0001 2163 4895 grid.28056.39 State Key Laboratory of Bioreactor Engineering East China University of Science and Technology 130 Meilong Road 200237 Shanghai China
| | - Lei Shi
- 0000 0001 2163 4895 grid.28056.39 State Key Laboratory of Bioreactor Engineering East China University of Science and Technology 130 Meilong Road 200237 Shanghai China
| | - Yuanxing Zhang
- 0000 0001 2163 4895 grid.28056.39 State Key Laboratory of Bioreactor Engineering East China University of Science and Technology 130 Meilong Road 200237 Shanghai China
- 0000 0001 2163 4895 grid.28056.39 School of Biotechnology East China University of Science and Technology 130 Meilong Road 200237 Shanghai China
- Shanghai Collaborative Innovation Center for Biomanufacturing 130 Meilong Road 200237 Shanghai China
| | - Xiangshan Zhou
- 0000 0001 2163 4895 grid.28056.39 State Key Laboratory of Bioreactor Engineering East China University of Science and Technology 130 Meilong Road 200237 Shanghai China
- 0000 0001 2163 4895 grid.28056.39 School of Biotechnology East China University of Science and Technology 130 Meilong Road 200237 Shanghai China
| | - Menghao Cai
- 0000 0001 2163 4895 grid.28056.39 State Key Laboratory of Bioreactor Engineering East China University of Science and Technology 130 Meilong Road 200237 Shanghai China
- 0000 0001 2163 4895 grid.28056.39 School of Biotechnology East China University of Science and Technology 130 Meilong Road 200237 Shanghai China
| |
Collapse
|
7
|
Methanol-Independent Protein Expression by AOX1 Promoter with trans-Acting Elements Engineering and Glucose-Glycerol-Shift Induction in Pichia pastoris. Sci Rep 2017; 7:41850. [PMID: 28150747 PMCID: PMC5288789 DOI: 10.1038/srep41850] [Citation(s) in RCA: 71] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Accepted: 12/29/2016] [Indexed: 01/02/2023] Open
Abstract
The alcohol oxidase 1 promoter (PAOX1) of Pichia pastoris is commonly used for high level expression of recombinant proteins. While the safety risk of methanol and tough process control for methanol induction usually cause problems especially in large-scale fermentation. By testing the functions of trans-acting elements of PAOX1 and combinatorially engineering of them, we successfully constructed a methanol-free PAOX1 start-up strain, in which, three transcription repressors were identified and deleted and, one transcription activator were overexpressed. The strain expressed 77% GFP levels in glycerol compared to the wide-type in methanol. Then, insulin precursor (IP) was expressed, taking which as a model, we developed a novel glucose-glycerol-shift induced PAOX1 start-up for this methanol-free strain. A batch phase with glucose of 40 g/L followed by controlling residual glucose not lower than 20 g/L was compatible for supporting cell growth and suppressing PAOX1. Then, glycerol induction was started after glucose used up. Accordingly, an optimal bioprocess was further determined, generating a high IP production of 2.46 g/L in a 5-L bioreactor with dramatical decrease of oxygen consumption and heat evolution comparing with the wild-type in methanol. This mutant and bioprocess represent a safe and efficient alternative to the traditional glycerol-repressed/methanol-induced PAOX1 system.
Collapse
|
8
|
Polez S, Origi D, Zahariev S, Guarnaccia C, Tisminetzky SG, Skoko N, Baralle M. A Simplified and Efficient Process for Insulin Production in Pichia pastoris. PLoS One 2016; 11:e0167207. [PMID: 27907132 PMCID: PMC5131935 DOI: 10.1371/journal.pone.0167207] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Accepted: 11/10/2016] [Indexed: 01/15/2023] Open
Abstract
A significant barrier to insulin is affordability. In this manuscript we describe improvements to key steps in the insulin production process in Pichia pastoris that reduce cost and time. The strategy for recovery and processing of human insulin precursor has been streamlined to two steps from bioreactor to the transpeptidation reaction. In the first step the insulin precursor secreted during the methanol induction phase is recovered directly from the culture broth using Tangential Flow Filtration with a Prostak™ module eliminating the laborious and time-consuming multi-step clarification, including centrifugation. In the second step the protein is applied at very high loadings on a cation exchange resin and eluted in a mixture of water and ethanol to obtain a concentrated insulin precursor, suitable for use directly in the transpeptidation reaction. Overall the yield from insulin precursor to human insulin was 51% and consisted of three purification chromatography steps. In addition we describe a method for recovery of the excess of H-Thr(tBu)-OtBu from the transpeptidation reaction mixture, one of the more costly reagents in the process, along with its successful reuse.
Collapse
Affiliation(s)
| | - Domenico Origi
- Biomanufacturing Sciences Network, Process Solutions, Merck SpA, Vimodrone (Milan), Italy
| | | | | | | | | | | |
Collapse
|
9
|
Aizen J, Chandler JC, Fitzgibbon QP, Sagi A, Battaglene SC, Elizur A, Ventura T. Production of recombinant insulin-like androgenic gland hormones from three decapod species: In vitro testicular phosphorylation and activation of a newly identified tyrosine kinase receptor from the Eastern spiny lobster, Sagmariasus verreauxi. Gen Comp Endocrinol 2016; 229:8-18. [PMID: 26883686 DOI: 10.1016/j.ygcen.2016.02.013] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Revised: 02/05/2016] [Accepted: 02/12/2016] [Indexed: 10/22/2022]
Abstract
In crustaceans the insulin-like androgenic gland hormone (IAG) is responsible for male sexual differentiation. To date, the biochemical pathways through which IAG exerts its effects are poorly understood and could be elucidated through the production of a functional recombinant IAG (rIAG). We have successfully expressed glycosylated, biologically active IAG using the Pichia pastoris yeast expression system. We co-expressed recombinant single-chain precursor molecules consisting of the B and A chains (the mature hormone) tethered by a flexible linker, producing rIAGs of the following commercially important species: Eastern spiny lobster Sagmariasus verreauxi (Sv), redclaw crayfish Cherax quadricarinatus (Cq) and giant freshwater prawn Macrobrachium rosenbergii (Mr). We then tested the biological activity of each, through the ability to increase phosphorylation in the testis; both Sv and Cq rIAGs significantly elevated phosphorylation specific to their species, and in a dose-dependent manner. Mr rIAG was tested on Macrobrachium australiense (Ma), eliciting a similar response. Moreover, using bioinformatics analyses of the de novo assembled spiny lobster transcriptome, we identified a spiny lobster tyrosine kinase insulin receptor (Sv-TKIR). We validated this discovery with a receptor activation assay in COS-7 cells expressing Sv-TKIR, using a reporter SRE-LUC system designed for RTKs, with each of the rIAG proteins acting as the activation ligand. Using recombinant proteins, we aim to develop specific tools to control sexual development through the administration of IAG within the critical sexual differentiation time window. The biologically active rIAGs generated might facilitate commercially feasible solutions for the long sought techniques for sex-change induction and monosex population culture in crustaceans and shed new light on the physiological mode of action of IAG in crustaceans.
Collapse
Affiliation(s)
- Joseph Aizen
- Faculty of Science, Health, Education and Engineering, GeneCology Research Centre, University of the Sunshine Coast, Queensland 4558, Australia
| | - Jennifer C Chandler
- Faculty of Science, Health, Education and Engineering, GeneCology Research Centre, University of the Sunshine Coast, Queensland 4558, Australia
| | - Quinn P Fitzgibbon
- Fisheries and Aquaculture, Institute for Marine and Antarctic Studies, University of Tasmania, Hobart, Tasmania, Australia
| | - Amir Sagi
- Department of Life Sciences and The National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Stephen C Battaglene
- Fisheries and Aquaculture, Institute for Marine and Antarctic Studies, University of Tasmania, Hobart, Tasmania, Australia
| | - Abigail Elizur
- Faculty of Science, Health, Education and Engineering, GeneCology Research Centre, University of the Sunshine Coast, Queensland 4558, Australia
| | - Tomer Ventura
- Faculty of Science, Health, Education and Engineering, GeneCology Research Centre, University of the Sunshine Coast, Queensland 4558, Australia.
| |
Collapse
|
10
|
Meehl MA, Stadheim TA. Biopharmaceutical discovery and production in yeast. Curr Opin Biotechnol 2014; 30:120-7. [PMID: 25014890 DOI: 10.1016/j.copbio.2014.06.007] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2014] [Revised: 05/15/2014] [Accepted: 06/08/2014] [Indexed: 01/02/2023]
Abstract
The selection of an expression platform for recombinant biopharmaceuticals is often centered upon suitable product titers and critical quality attributes, including post-translational modifications. Although notable differences between microbial, yeast, plant, and mammalian host systems exist, recent advances have greatly mitigated any inherent liabilities of yeasts. Yeast expression platforms are important to both the supply of marketed biopharmaceuticals and the pipelines of novel therapeutics. In this review, recent advances in yeast-based expression of biopharmaceuticals will be discussed. The advantages of using glycoengineered yeast as a production host and in the discovery space will be illustrated. These advancements, in turn, are transforming yeast platforms from simple production systems to key technological assets in the discovery and selection of biopharmaceutical lead candidates.
Collapse
Affiliation(s)
- Michael A Meehl
- GlycoFi, Biologics Research, Merck & Co., Inc., 16 Cavendish Court, Lebanon, NH 03766, USA
| | - Terrance A Stadheim
- GlycoFi, Biologics Research, Merck & Co., Inc., 16 Cavendish Court, Lebanon, NH 03766, USA.
| |
Collapse
|
11
|
Liu H, Zhou X, Tian S, Hao X, You J, Zhang Y. Two-step transpeptidation of the insulin precursor expressed in Pichia pastoris to insulin ester via trypsin-catalyzed cleavage and coupling. Biotechnol Appl Biochem 2013; 61:408-17. [PMID: 24325254 DOI: 10.1002/bab.1186] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2013] [Accepted: 12/05/2013] [Indexed: 11/07/2022]
Abstract
Insulin precursor fusion protein expressed in Pichia pastoris is a single-chain protein with a spacer peptide (EEAEAEAEPK) localized at its N-terminal. Currently, the one-step transpeptidation reaction with low yield and high cost is generally employed to convert the insulin precursor fusion protein into human insulin ester. In this study, a two-step transpeptidation reaction was proposed separating the cleavage step from the coupling step so that each reaction was performed under its optimal conditions. Using this method, the total efficiency doubled and the reaction time was shortened compared with the one-step method. In addition, the amount of O-t-butyl-l-threonine t-butyl ester and trypsin dosages were reduced by 50% and 75%, respectively. This two-step transpeptidation strategy was simple and efficient and could be used for the pharmaceutical production of human insulin.
Collapse
Affiliation(s)
- Haifeng Liu
- State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, People's Republic of China.,Shandong Dong-e E-Jiao Co., Ltd., Shandong, People's Republic of China.,Shandong Ehua Biopharmaceutical Co., Ltd., Shandong, People's Republic of China
| | - Xiangshan Zhou
- State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, People's Republic of China
| | - Shousheng Tian
- Shandong Dong-e E-Jiao Co., Ltd., Shandong, People's Republic of China
| | - Xianghui Hao
- Shandong Dong-e E-Jiao Co., Ltd., Shandong, People's Republic of China
| | - Jinhua You
- Shandong Dong-e E-Jiao Co., Ltd., Shandong, People's Republic of China.,Shandong Ehua Biopharmaceutical Co., Ltd., Shandong, People's Republic of China
| | - Yuanxing Zhang
- State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, People's Republic of China
| |
Collapse
|
12
|
Liu H, Zhou X, Xie F, You J, Zhang Y. An efficient trypsin digestion strategy for improving desB30 productivity from recombinant human insulin precursor fusion protein. Process Biochem 2013. [DOI: 10.1016/j.procbio.2013.04.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
13
|
Feng F, Hu P, Chen L, Tang Q, Lian C, Yao Q, Chen K. Display of Human Proinsulin on the Bacillus subtilis Spore Surface for Oral Administration. Curr Microbiol 2013; 67:1-8. [DOI: 10.1007/s00284-013-0325-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2013] [Accepted: 01/22/2013] [Indexed: 11/29/2022]
|
14
|
Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulin. Microb Cell Fact 2010; 9:31. [PMID: 20462406 PMCID: PMC2882349 DOI: 10.1186/1475-2859-9-31] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2010] [Accepted: 05/12/2010] [Indexed: 12/22/2022] Open
Abstract
Background The prevalence of diabetes is predicted to rise significantly in the coming decades. A recent analysis projects that by the year 2030 there will be ~366 million diabetics around the world, leading to an increased demand for inexpensive insulin to make this life-saving drug also affordable for resource poor countries. Results A synthetic insulin precursor (IP)-encoding gene, codon-optimized for expression in P. pastoris, was cloned in frame with the Saccharomyces cerevisiae α-factor secretory signal and integrated into the genome of P. pastoris strain X-33. The strain was grown to high-cell density in a batch procedure using a defined medium with low salt and high glycerol concentrations. Following batch growth, production of IP was carried out at methanol concentrations of 2 g L-1, which were kept constant throughout the remaining production phase. This robust feeding strategy led to the secretion of ~3 gram IP per liter of culture broth (corresponding to almost 4 gram IP per liter of cell-free culture supernatant). Using immobilized metal ion affinity chromatography (IMAC) as a novel approach for IP purification, 95% of the secreted product was recovered with a purity of 96% from the clarified culture supernatant. Finally, the purified IP was trypsin digested, transpeptidated, deprotected and further purified leading to ~1.5 g of 99% pure recombinant human insulin per liter of culture broth. Conclusions A simple two-phase cultivation process composed of a glycerol batch and a constant methanol fed-batch phase recently developed for the intracellular production of the Hepatitis B surface antigen was adapted to secretory IP production. Compared to the highest previously reported value, this approach resulted in an ~2 fold enhancement of IP production using Pichia based expression systems, thus significantly increasing the efficiency of insulin manufacture.
Collapse
|